Welcome to our dedicated page for Affimed SEC filings (Ticker: AFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Access the historical SEC filings archive for Affimed N.V. (AFMD), a clinical-stage biopharmaceutical company that previously traded on NASDAQ before being delisted. These regulatory documents chronicle the company's financial history, clinical development activities, and the circumstances surrounding its transition from active trading.
Affimed's SEC filings provide insight into how a development-stage immuno-oncology company reported its operations. As a company without product revenue, Affimed's 10-K annual reports and 10-Q quarterly filings detailed research spending, clinical trial expenses, and the cash requirements of advancing bispecific antibody candidates through development. The filings reveal how biotechnology companies communicate pipeline progress and risk factors to investors.
Form 4 insider transaction records document how executives and directors managed their equity positions during the company's time as a public entity. These filings provide transparency into insider activity patterns at a clinical-stage biotechnology company.
The 8-K material event filings capture significant corporate developments, including clinical data announcements, partnership agreements, and regulatory interactions. For companies like Affimed operating in immuno-oncology, 8-K filings often disclosed trial updates and scientific presentations that moved the stock price.
This archive includes the 25-NSE delisting notification, confirming the removal of Affimed shares from NASDAQ listing. Researchers and investors studying biotechnology company lifecycles may find these historical documents valuable for understanding the regulatory filing patterns of clinical-stage companies and the disclosures surrounding corporate difficulties.
Nasdaq Stock Market LLC has filed Form 25 to strike Affimed N.V. (AFMD) common stock from listing and registration under Section 12(b) of the Exchange Act. The notification, signed on 2025-07-21 by a Nasdaq hearings advisor, states that the exchange believes it meets all regulatory requirements for delisting. No financial results, trading data, or rationale are provided in the filing.
The action will remove AFMD from the Nasdaq Global Market once the SEC’s 10-day period elapses, and registration under Section 12(g) will be terminated after 90 days unless the company files contrary documentation. Investors should anticipate the stock moving to an over-the-counter venue or another exchange, subject to separate listing standards.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
